BACKGROUND: Sepsis refers to the dysregulated host immune response elicited by microbial infections resulting in life-threatening organ dysfunction. Sepsis represents a medical challenge, since it is associated with a rate of death as high as 60%. Septic shock is strongly associated with vascular dysfunction and elevated pulmonary capillary permeability. We recently reported that the combination of hydrocortisone (HC), ascorbic acid (vitC), and thiamine dramatically improves outcomes and reduces mortality in patients with sepsis. In the present study, we provide experimental evidence in support of the hypothesis that the combination of HC and vitC enhances endothelial barrier function.
Deviations from normal endothelial barrier function can lead to or be caused by various internal or external stresses and pathologic conditions. 1 Sepsis and septic shock, as recently redefined, 2 are associated with pulmonary edema caused by increased permeability to proteins across pulmonary endothelial and epithelial barriers, 3 and recovery from septic shock is associated with a reduction in edema, consistent with restoration of vascular function. 4 The regulation of vascular permeability is tightly coordinated by a variety of intracellular factors and external stimuli. 5 It is increased by inflammatory factors, such as histamine, bradykinin, plateletactivating factor, growth factors, glycation products, cytokines, reactive oxygen species, and activated leukocytes. 6, 7 These mediators trigger signaling cascades that modulate the expression of junctional proteins and adhesion molecules, as well as the reorganization of the cytoskeleton and focal adhesion complexes, 8 all leading to compromised barrier integrity. 7 Sepsis is an insidious pathologic condition that despite years of research and numerous clinical trials levies a death rate of approximately 40%. 9, 10 We recently reported on the strikingly beneficial effects of combined hydrocortisone (HC) and ascorbic acid (vitC) therapy in patients with sepsis. 3 Compared with patients receiving standard-care therapy, those receiving HC and vitC exhibited dramatically reduced mortality (40% vs 8%), a reduced requirement for pressor agent support, and decreasing Sequential Organ Failure Assessment scores and procalcitonin blood levels. We speculated that at least part of these actions of HC and vitC might involve restoration of endothelial barrier function. 3 Thus, the current study examines the effect of HC and vitC on lipopolysaccharide (LPS)-induced vascular dysfunction. HC is a corticosteroid that exhibits anti-inflammatory effects, increases systemic vascular resistance, and potentiates the vasoconstrictive responses of catecholamines and angiotensin II. 11 It is effective against ischemia/ reperfusion injury by mediating the nontranscriptional activation of endothelial nitric oxide synthase. 12 It prevents the migration of inflammatory cells from the circulation to tissues by blocking the synthesis of various chemokines and cytokines. 13 vitC is a potent antioxidant that has long been known to participate in several important vascular endothelial functions, including increasing the synthesis and deposition of type IV collagen in the basement membrane, stimulating endothelial proliferation, inhibiting apoptosis, scavenging radical species, and increasing the bioavailability of nitric oxide to help modulate blood flow.
14 Both drugs inhibit nuclear factor-kB activation and downregulate the production of proinflammatory mediators. Furthermore, they increase tight junctions between endothelial and epithelial cells, which preserves endothelial function and microcirculatory flow. In addition, both are required for the synthesis of catecholamines, and both increase vascular vasopressor sensitivity. 3 LPS is the major component of the outer wall of gramnegative bacteria. It activates macrophages, neutrophils, and dendritic and other cells that induce inflammation, oxidative stress, and endothelial damage. 15 Exposure to LPS leads to endothelial barrier dysfunction, a hallmark of acute lung injury, ARDS, and sepsis. 16, 17 Our observations reveal that pretreatment of human lung microvascular endothelial cells (HLMVECS) with both compounds together, but not separately, reverses the LPS-induced endothelial barrier dysfunction. Furthermore, we show that this protective effect occurs through the induction of p53 and phosphorylated cofilin and the downregulation of the RhoA/myosin light chain 2 (MLC2) pathway. In house, HLMVECs were harvested and maintained as previously described. 18 Briefly, subpleural lung tissue was cut into small fragments with scissors. After the removal of debris and erythrocytes through a 40-mm nylon net, the tissue collected in the net was treated with dispase, filtered through a 100-mm nylon net (2 times) and then a 40-mm net, centrifuged, and resuspended in Medium 199 (Gibco; Catalog No. 31100-019) with 20% fetal bovine serum. Positive selection of HLMVECs was achieved by adding magnetic beads coated with Ulex europaeus I to the cell suspension.
The barrier function of endothelial cell monolayers was estimated by the electric cell-substrate impedance sensing method, as previously described. 15 Experiments were conducted on wells that achieved at least 800 U baseline steady-state resistance. Proteins were isolated from cells, and samples (40 mg per lane) were separated by electrophoresis, as previously described. 16 Band density was visualized in a LI-COR Odyssey CLx imaging system. Data are expressed as means AE SEM. Two-way analysis of variance with Bonferroni correction (Figs 1-3) or one-way analysis of variance with Dunnett's post hoc test (Figs 4-8 ) was performed to determine differences among groups. GraphPad Prism (GraphPad Software) was used for data analysis, and n ¼ the number of repeats.
Results

vitC Does Not Affect Endothelial Barrier Function
HLMVECs seeded on gold electrode arrays were exposed to phosphate-buffered saline (PBS) (vehicle) 250 mM, 500 mM or 1,000 mM vitC. vitC did not induce a biologically significant effect on transendothelial electrical resistance (TEER) (Fig 1A) . In additional experiments, HLMVECs were exposed to either vehicle (PBS) or 1, 000 mM vitC before treatment with PBS or LPS (0.5 endotoxin units [EU]/mL). LPS decreased TEER values of both vehicle-treated and vitC-treated HLMVECs. There was no difference in TEER values between the two LPS-treated groups ( Fig 1B) . 
Effects of HC on Endothelial Barrier Function
HLMVECs were exposed to PBS and 4 mM or 6 mM HC. HC induced a concentration-dependent but biologically miniscule enhancement of barrier function (Fig 2A) . In additional experiments, HLMVECs were exposed to PBS or HC (4 mM) for 16 hours prior to PBS or LPS (0.5 EU/mL) treatment. Cells treated with PBS maintained stable TEER values, whereas cells treated with HC exhibited moderately increased barrier function. LPS caused a sharp decrease in TEER, which was only partially and moderately ameliorated by pretreatment with HC ( Fig 2B) .
The Combination of HC and vitC Prevents and Repairs the LPS-Induced Endothelial Barrier Dysfunction
HLMVECs were pretreated (Fig 3A) or posttreated ( Fig 3B) with either vehicle or a combination of HC (4 mM) and vitC (1,000 mM) 16 hours prior to or 15 min after challenge with LPS (0.5 EU/mL) or PBS. PBS alone did not influence TEER values, which remained steady throughout the course of the study. As expected, LPS induced a robust decrease in TEER. However, cells pretreated or posttreated with HC and vitC exhibited complete restoration of barrier function. To investigate whether the effect of LPS was at least in part due to cell death, we evaluated HLMVEC viability after LPS by the trypan blue dye exclusion method. At 0.5 EU/mL (the concentration used throughout this study), LPS did not affect cell viability; however, cell death was observed at 20 times higher concentrations (Fig 4) .
Since it appeared that HC and vitC together, but not separately, were able to prevent LPS-induced barrier dysfunction, we then investigated possible mechanisms responsible for these effects. Figure 1 legend for expansion of other abbreviations.
The Combination of HC and vitC Prevents LPS-Induced p53 Downregulation in HLMVECs
We have reported that LPS reduces p53 levels and that p53 overexpression is associated with endothelial barrier enhancement. 16 We thus investigated the ability of HC plus vitC to affect p53 expression. HLMVECs were exposed to PBS, HC (4 mM), and vitC (1,000 mM) prior to LPS (0.5 EU/mL) or vehicle treatment. p53 expression was examined by Western blotting 1 hour after exposure to LPS. LPS induced profound p53 downregulation, in line with our previous reports. 16, 19 HC plus vitC-treated cells exhibited normal p53 levels (Fig 5) .
The Combination of HC and vitC Prevents the LPS-Induced Cofilin Activation (Dephosphorylation) in HLMVECs
Cofilin is a b-actin interacting protein that promotes stress fiber formation. HLMVECs were exposed to PBS, HC (4 mM), and vitC (1,000 mM) before LPS (0.5 EU/ mL) or vehicle treatment. Active (dephosphorylated) and inactive (phosphorylated) cofilin expression was examined by Western blotting 1 hour after LPS. LPS induced significant activation of cofilin consistent with the known formation of stress fibers. HC plus vitC-treated cells exhibited normal inactive cofilin levels (Fig 6) .
The Combination of HC and vitC Prevents LPS-Induced RhoA Activation in HLMVECs
The RhoA pathway is a well-known mediator of endothelial barrier dysfunction. HLMVECs were exposed to PBS, HC (4 mM), and vitC (1,000 mM) before chestjournal.org LPS (0.5 EU/mL) or vehicle treatment. Active and total RhoA levels were examined 1 hour after LPS. LPS induced strong RhoA activation, in line with our previous reports. 16, 19 HC plus vitC-treated cells exhibited normally low active RhoA levels (Fig 7) .
The Combination of HC and vitC Prevents the LPS-Induced Activation (Phosphorylation) of MLC2 in HLMVECs MLC2 activation by myosin light chain kinase or Rho kinase is responsible for actin stress fiber formation.
HLMVECs were exposed to PBS, HC (4 mM), and vitC (1,000 mM) before LPS (0.5 EU/mL) or vehicle treatment. Phosphorylated and nonphosphorylated MLC2 levels were measured by Western blotting 1 hour after LPS exposure. LPS induced significant MLC2 phosphorylation, consistent with our previous reports. 16, 19 HC plus vitC-treated cells exhibited baseline nonphosphorylated MLC2 levels (Fig 8) .
Discussion
Sepsis is a systemic inflammatory response to infection from multiple causes. Severe sepsis describes instances in which sepsis is complicated by acute organ dysfunction and the provision of supportive therapy, such as mechanical ventilation, is required. 20 In the United
States, severe sepsis is recorded in 750,000 patients per year. That number represents 2% of all patients admitted to the hospital.
Sepsis is associated with microvascular thrombosis and impairment of anticoagulation mechanisms. Tissue oxygenation is further impaired by the loss of the endothelial barrier function. 20 Oxygen use is impaired at the subcellular level because of damage to mitochondria from oxidative stress.
21
vitC is an antioxidant that can improve the endothelium-dependent response in circumstances such as chronic smoking, diabetes mellitus, hypercholesterolemia, and hypertension. 22-24 vitC protects the endothelium by scavenging superoxide, which in turn prevents nitric oxide scavenging, lipid peroxidation, platelet and neutrophil activation, and adhesion molecule upregulation. 25 It scavenges peroxidase-generated reactive nitrogen species and inhibits low-density lipoprotein oxidation. 26 It further acts as a lipid-soluble antioxidant, scavenging hydroperoxyl radicals in lipid milieu. 27 vitC alone fails to protect endothelial function against toxic insults. Administration of oral ascorbate (1,500 mg/d) in combination with other antioxidants failed to decrease mortality in critically ill adults with multiorgan failure. 28 Similar negative results were observed in a mouse model of sepsis. 29, 30 The use of glucocorticosteroids (GCs) such as HC in the treatment of sepsis remains controversial. Short treatment of gram-negative bacteria with high-dose GCs in healthy volunteers was ineffective in the majority of studies. 31 GCs failed to attenuate the LPS-induced coagulation cascade in humans 32 and failed to inhibit LPS-induced nuclear factor-kB translocation in human monocytes. 33 In contrast, stratification of mice according to levels of circulating interleukin (IL)-6 predicted mortality as well as the efficacy of GC treatment; mice with high levels of IL-6 responded to GCs.
34
A recent study by Azari et al 35 evaluated the protective effects of HC, vitC, and vitamin E alone or in combination against renal ischemia/reperfusion injury in rats. The inevitable injuries may occur after infarction, sepsis, and organ transplantation, and this phenomenon exacerbates tissue damage by initiating an inflammatory cascade including reactive oxygen species, cytokines, chemokines, and leukocyte activation. 36 Combined administration of vitC, vitamin E, and HC before restoration of blood flow to the ischemic tissue had a synergistic protective effect against the deleterious effects of ischemia/reperfusion injury to the kidney. 35 In a recent retrospective before/after clinical study, we compared the outcome and clinical course of patients with sepsis treated with IV vitC, HC, and thiamine during a 7-month period (treatment group) compared with a control group receiving standard-care therapy during the preceding 7 months. There were 47 patients in each group with no significant differences in baseline characteristics. Hospital mortality was 8.5% (four of 47 patients) in the treatment group compared with 40.4% (19 of 47 patients) in the control group. Sequential Organ Failure Assessment scores decreased in all patients in the treatment group, with none experiencing progressive organ failure. These results suggested that the early use of IV vitC together with corticosteroids and thiamine is effective in preventing progressive organ dysfunction, including acute kidney injury, and reducing the mortality of patients with severe sepsis and septic shock. 3 We recently demonstrated that silencing of p53 in HLVMECs profoundly disrupts their barrier function. 16 To evaluate whether p53 is involved in the "rescue" of the LPS-induced vascular dysfunction by the combination of vitC and HC, we examined the effect of these compounds in HLMVECs. In line with previous observations, 16 a significant decrease in p53 expression was observed after 1 hour of LPS treatment, which was absent in cells pretreated with vitC and HC, reflecting their protective effect against vascular injury.
Cofilin is an actin-severing protein that is tightly associated with the regulation of cellular motion and vascular permeability. Rac1 activation leads to phosphorylation (deactivation) of cofilin. 37 Furthermore, the small guanosine triphosphate RhoA and its downstream target Rho kinase also regulate cellular adherence through control of the actincytoskeletal assembly and cell contraction. RhoA directly phosphorylates MLC2, which in turn can trigger contraction, resulting in endothelial cell membrane retraction, intercellular gap formation, and barrier compromise. 38 In the current study, we observed that LPS resulted in reduced cofilin phosphorylation, ie, activation and increased RhoA activation and myosin light chain phosphorylation. This agrees with other observations and suggests a similar association between LPS and cofilin or RhoA-induced hyperpermeability. 39 Pretreatment of HLMVECs with HC and vitC prevented the LPS-mediated cofilin and RhoA activation, which is in agreement with the observed reversal of the LPSinduced decrease in TEER.
Conclusions
We introduce for the first time, to our knowledge, a mechanism that is responsible, at least in part, for the protective effect of the synergistic action of HC and vitC on LPS-induced hyperpermeability. The aforementioned findings should be seen in conjunction with a recent report 3 demonstrating that early use of IV vitC, together with HC and thiamine, are effective in preventing progressive organ dysfunction due to severe sepsis and septic shock. Collectively, these findings provide a new and exciting approach to the management of severe sepsis.
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